Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Benzinga

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.

Investors Business Daily

The Latest: US trade partners around the world react to Trump's new tariffs

U.S. trade partners are reacting to President Donald Trump’s executive order that would introduce new tariffs on many of them in seven days

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

First malaria treatment for babies is a major step to ending the disease in Africa - biochemist

The first malaria treatment for babies and very young children of 2 months up to 5 years was approved for use by Swiss agency for therapeutic products, Swissmedic, in early July 2025. Until now, babies and very young children have been treated with medicines formulated for older children.

The Conversation

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety profile of Elevidys.

Investors Business Daily

Novartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs Misses

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Investors Business Daily

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hope for developing world as Swiss anti-malarial for newborns approved

IN FULL

The Independent UK

First anti-malaria drug for newborns approved

The newly approved medication is a lower-dose version of a tablet previously approved for other age groups

The Independent UK

World’s first malaria treatment for newborn babies gets approval

Several African countries where malaria is widespread are expected to swiftly approve the new medicine following Swissmedic’s decision.

Euronews

Can Biogen Save Even More Kids With This New Drug?

Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.

Investors Business Daily

Stocks With Rising Relative Strength: Novartis ADR

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?

Investors Business Daily

Americans would suffer most if Trump imposes pharma tariffs, sector warns

Industry says levies would hit supply chains, making medicines potentially unaffordable for some US patients

The Guardian - UK

Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

Euronews

Novartis posts better-than-expected sales driven by medicine demand

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.

MarketBeat

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

The Independent UK

Pill that slashes risk of breast cancer recurring to be available on NHS

Ribociclib (known by the brand name Kisqali) targets specific proteins that contribute to cancer cell growth

Get all your
news in one place.

100’s of premium titles.
One news app.

Euronews

EU holds firm on pharma reform proposal despite industry pressure

The European Commission has no plans to withdraw or revise its proposed overhaul of EU pharmaceutical rules, despite mounting pressure from the pharmaceutical industry concerned about potential tariffs and the sector’s competitiveness.

Latin Times

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Fortune

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

Investors Business Daily

Novartis ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance.

Latin Times

Novartis Plans $23 Billion US Buildout as Pharma Faces Pressure From Trump

Novartis plans a $23 billion U.S. expansion to boost drug production and counter potential import tariffs.

Fortune

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Investors Business Daily

Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

the European Parliament

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.